| Bioactivity | Lorvotuzumab mertansine is an ADC consisting of a humanized N901 monoclonal antibody against CD56 bound to maytansinoid DM1 via a stable disulfide linker. Lorvotuzumab mertansine has antitumor activity[1]. |
| Invitro | Lorvotuzumab mertansine（0.001-100 nM，8 天）对这两个细胞系显示出靶向细胞杀伤活性，作用于 NCI-H526 细胞系的 IC50值为0.2 nM，NCI-H69 细胞系为 5 nM[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Lorvotuzumab mertansine 相关抗体: |
| In Vivo | Lorvotuzumab mertansine（3-51 mg/kg，静脉注射，一次）在 CB.17 SCID 小鼠 SW2 SCLC 异种移植肿瘤中具有强大的抗肿瘤活性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 1008106-64-6 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kathleen R Whiteman, et al. Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. MAbs. 2014 Mar-Apr;6(2):556-66. |